Shilpa Medicare is currently trading near ₹490 after delivering a strong breakout above the ₹420–430 resistance zone. The stock has formed a clean Stage-2 uptrend with higher highs and higher lows, while sustaining above its key moving averages. Price action now indicates institutional-style accumulation, with strong acceptance above the previous value area instead of immediate rejection.
Fundamentally, FY26 was the company’s strongest year yet with revenue reaching ₹1,549 crore, EBITDA touching a record ₹445 crore, and Adjusted PAT surging 135% to ₹232 crore. Management also guided for margin recovery toward 9.5–11% from 8.7% in Q3, supported by Oncology API demand and CDMO growth visibility. The recent Latin America biosimilar licensing deal further strengthens the long-term growth narrative.
Technically, the breakout structure remains healthy as buyers repeatedly defended the ₹470–480 region. Volume profile shows heavy accumulation near ₹410–430, while momentum expansion above ₹500 could trigger another leg higher. Relative strength versus the pharma sector has also improved significantly over the past few weeks, which is usually a bullish sign for swing continuation.
As long as the stock sustains above ₹470, the probability of continuation toward ₹560, ₹590, and potentially ₹620 over the next 6–8 weeks remains strong. Compared to highly speculative pharma names, Shilpa currently offers a better balance of earnings quality, technical structure, and momentum sustainability for a potential 20–30% swing setup.
Fundamentally, FY26 was the company’s strongest year yet with revenue reaching ₹1,549 crore, EBITDA touching a record ₹445 crore, and Adjusted PAT surging 135% to ₹232 crore. Management also guided for margin recovery toward 9.5–11% from 8.7% in Q3, supported by Oncology API demand and CDMO growth visibility. The recent Latin America biosimilar licensing deal further strengthens the long-term growth narrative.
Technically, the breakout structure remains healthy as buyers repeatedly defended the ₹470–480 region. Volume profile shows heavy accumulation near ₹410–430, while momentum expansion above ₹500 could trigger another leg higher. Relative strength versus the pharma sector has also improved significantly over the past few weeks, which is usually a bullish sign for swing continuation.
As long as the stock sustains above ₹470, the probability of continuation toward ₹560, ₹590, and potentially ₹620 over the next 6–8 weeks remains strong. Compared to highly speculative pharma names, Shilpa currently offers a better balance of earnings quality, technical structure, and momentum sustainability for a potential 20–30% swing setup.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.